[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Oran 1\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100640507","essential-oils-for-urinary-symptoms-in-multiple-sclerosis-patients-100640507",false,"NCT07599189","Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients","Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.","AROMA-MS","Inclusion Criteria:\n\n* Confirmed diagnosis of Multiple Sclerosis (any form)\n* Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening\n* Age between 18 and 65 years\n* Willing and able to provide written informed consent\n* Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period\n\nExclusion Criteria:\n\n* Active urinary tract infection confirmed by urine culture at screening\n* Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)\n* Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary\n* Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application\n* Pregnancy, breastfeeding, or planning to become pregnant during the study period\n* Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires\n* Current use of an indwelling urinary catheter or practice of intermittent self-catheterization","ALL",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.\n\nThe main questions it aims to answer are:\n\n* Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?\n* What medical problems do participants have when using essential oil aromatherapy?\n\nResearchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.\n\nParticipants will:\n\n* Use essential oil aromatherapy or a placebo oil every day for 6 weeks\n* Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day\n* Fill out quality of life questionnaires at the beginning and end of the study",[26,27,28,29,30],"Multiple Sclerosis (MS)","Neurogenic Bladder Disorder","Urinary Incontinence (UI)","Urinary Urgency","Lower Urinary Tract Symptoms (LUTS)","NOT_YET_RECRUITING","2026-05-16",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":20},"2026-09",{"date":39,"type":20},"2027-03",{"name":41,"class":42},"University of Oran 1","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":65,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100553047","algerian-cholecystectomy-outcomes-and-determinants-study-al-cods-100553047","NCT06481007","ALgerian Cholecystectomy Outcomes and Determinants Study (AL-CODS)","Algerian Cholecystectomy Outcomes and Determinants Study","AL-CODS","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Undergoing cholecystectomy.\n* Surgery performed in public or private hospitals in Algeria.\n* Surgery performed from January 1, 2025, to June 30, 2025.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients refusing to participate.\n* Cholecystectomy performed for Gallbladder cancer.\n* Cholecystectomy performed outside the inclusion period.\n* Cholecystectomies performed in conjunction with other major surgeries.","18 Years",{"count":53,"type":20},500,"1 Month","OBSERVATIONAL","Cholecystectomy, the surgical removal of the gallbladder, is a common procedure performed to treat benign gallbladder diseases such as cholelithiasis (gallstones), cholecystitis (inflammation of the gallbladder), and biliary dyskinesia. While generally considered safe, this surgery can be associated with significant morbidity and mortality, particularly in certain populations or healthcare settings. Understanding these outcomes and the factors influencing them is crucial for improving patient care and surgical practices.\n\nIn Algeria, the healthcare landscape presents unique challenges and opportunities for evaluating surgical outcomes. Limited studies have specifically focused on the morbidity and mortality associated with cholecystectomy in this context. This study aims to fill that gap by providing comprehensive data on 30-day postoperative outcomes following cholecystectomy for benign gallbladder diseases in Algeria. Such data is essential for benchmarking current practices, identifying areas for improvement, and ultimately enhancing patient safety and surgical efficacy.",[58,59,60,61,62,63,64],"Cholecystectomy","Adults","Gall Stone","Polyps","Pancreatitis Biliary","Gallbladder Dyskinesia","Cholecystitis",[66,58,67,68,69,70],"Algeria","mortality","morbidity","30 days","determinants","2024-06-26",{"date":73,"type":35},"2024-07-01",{"date":75,"type":20},"2025-01-01",{"date":77,"type":20},"2025-07-02",{"name":41,"class":42},""]